Coagulation Factor VIIa Articles
MediGene rated outperformer by MSDW
24 August 2000
Serono's Luveris gets CPMP backing
16 August 2000
Swiss pre-approval for Unigene's Forcaltonin
16 August 2000
Chiron Corp to acquire PathoGenesis for $700 million in cash
15 August 2000
Chiron second-quarter profits soar 70%
7 August 2000
Stock Commentary New York
3 August 2000
Stock Commentary Europe
3 August 2000
Quadrant signs hemophilia sugar deal
25 July 2000
Genset faces decisions over antiobesity agent
25 July 2000
AHP posts healthy 2nd quarter results
24 July 2000
Serono sees 2nd-qtr net income leap 60%
21 July 2000
Stock Commentary New York
13 July 2000
Avonex sales continue to boost Biogen
13 July 2000
Chiron's Proleukin shows promise in HIV
10 July 2000
Stock Commentary New York
6 July 2000
Bayer gets FDA OK for new Kogenate
3 July 2000
Nutropin Depot launched in USA
29 June 2000
Needle-free hGH from Serono approved in USA
26 June 2000
Connetics gets $20 million boost
23 June 2000
Serono plans $2B share offer, US filing
23 June 2000
Celltech delays BLA for CDP 571
20 June 2000
PowderJect gets L1 million from Serono
12 June 2000
Stock Commentary Tokyo
8 June 2000
Genentech reports positive anti-VEGF data
24 May 2000
Orphan drug status for rhATIII
11 May 2000
Orphan drug status for rhATIII
11 May 2000
HepaVec completes private financing
8 May 2000
Ares-Serono 1sr qtr net income leaps 39.2%
28 April 2000
Genzyme acquires Pompe disease therapy
26 April 2000
Xoma and Baxter see delayed Neuprex filing
26 April 2000
ICOS Corp halts LeukArrest study
26 April 2000
Lilly and Ono link up for sivelestat critical care drug
18 April 2000
Novartis acquires Grandis Biotech
14 April 2000
Connetics signs license deal with FH Faulding for ConXn
13 April 2000
Biotech-based protein drugs to surge ahead
12 April 2000
American Home Products reveals R&D pipeline
11 April 2000
Major vaccine project for BioChem Pharma
6 April 2000
Bayer's US health care sales jump 21% in 1999
31 March 2000
Bayer wins positive opinion for Kogenate
28 March 2000
Bayer structure to remain intact UPDATE
20 March 2000
Stock Commentary New York
16 March 2000
Serono "almost perfect biotech investment"
10 March 2000
Product pipeline pushes Pharming shares
6 March 2000
Novo Nordisk sales increase 17%
21 February 2000
Aventis and MediGene hook up for cancer vaccine
18 February 2000
Unstable angina, IBD market forecasts
15 February 2000
US orders expedited review of gene therapy guidelines
10 February 2000
Analysts enthuse about Ares-Serono
4 February 2000
Serono and AMRAD in infertility pact
1 February 2000
Amgen files first regulatory dossiers for NESP and Kineret
27 January 2000
$180M lawsuit bill hits Genentech earnings
21 January 2000
Ares-Serono sales hit $1 billion mark
19 January 2000
Genzyme Transgenics' antithrombin III, signs deal with Alexion
13 January 2000
Atrix Labs gets European backing for Atridox
11 January 2000
Schering-Plough files BLA for PEG-Intron
11 January 2000
Orchid Biocomputer raises $72 million
7 January 2000
Genentech begins pivotal trial of RhuMAb-VEGF
4 January 2000
Genentech's Nutropin Depot approved in USA
29 December 1999
Genentech boosted on asthma data, BLA 2000
21 December 1999
NABI sees promise with nicotine vaccine
21 December 1999
US gene therapy trial reports to be tightened
16 December 1999
Female infertility market forecasts to 2008
7 December 1999
Biogen starts Phase III trials of Amevive in plaque psoriasis
6 December 1999
S-P suffers after AE reports in gene therapy
24 November 1999
Cobra Therapeutics awarded "key DNA patent" in the USA
9 November 1999
Ares-Serono says sales "on track to exceed $1 billion in 1999"
4 November 1999
Chiron pleases analysts, cutting jobs
3 November 1999
VaxGen advances AIDS vaccine, raises $25m
21 October 1999
Wyeth-Lederle withdraws RotaShield vaccine - updated story
21 October 1999
Therion melanoma vaccines start Phase II trial at NCI
18 October 1999
Roche reducing stake in Genentech
11 October 1999
Biogen earnings rise 65% for third quarter
11 October 1999
Teva in $20 million alliance with BTG
11 October 1999
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
